MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases

-Collaboration includes licensing agreement option based on early-stage preclinical outcomes

LONDON--(BUSINESS WIRE)--MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need. The collaboration will allow for the discovery, and potential development and commercialization of RNAa therapeutic candidates targeting rare neurodegenerative diseases for which there are currently no treatment options.

Under the agreement, MiNA Therapeutics will utilize its proprietary RNAa algorithm and technology platform to identify and characterise RNAa molecules targeting rare genetic diseases of the central nervous system (CNS). Nippon Shinyaku will also have the option to exercise an exclusive license to further research, develop and commercialize pharmaceutical candidates based on early-stage preclinical outcomes.

"We are proud and excited to announce this collaboration with Nippon Shinyaku, who have prioritised rare genetic diseases as part of their impressive research and development capabilities,” said Robert Habib, Chief Executive Officer at MiNA. “Our RNAa therapeutic platform has delivered unique and differentiated clinical benefits in previous studies, demonstrating its potential to have significant benefits over other genetic medicine approaches.”

Nippon Shinyaku will pay MiNA an upfront payment and development milestone associated with delivering characterized RNAa molecules and, subject to exercising an exclusive option fee for further development and commercialization, milestones payments and royalties commensurate with progress and sales of the product(s) after launch. Financial terms of the agreement were not disclosed.

MiNA’s RNAa platform has been clinically validated in more than 120 patients to date. The universally designed platform has the potential to address any gene given its endogenous mechanism of action that ultimately addresses the root cause of the defective gene and enables the body to self-correct. Furthermore, working at the gene level, RNAa medicines have the ability to restore a cell’s own biology. This holds potential to treat currently “undruggable” diseases.

About Nippon Shinyaku

Based on Nippon Shinyaku’s business philosophy, “Helping people lead healthier, happier lives,” we aim to be an organization trusted by the community through creating unique medicines that will bring hope to patients and families suffering from illness. Please visit our website (https://www.nippon-shinyaku.co.jp/english/) for products or detailed information.

About MiNA Therapeutics

MiNA Therapeutics is the leader in small activating RNA therapeutics. Harnessing innate mechanisms of gene activation, small activating RNA therapeutics are a revolutionary new class of medicines that can restore normal function to patients’ cells. We are advancing a proprietary pipeline of new medicines with an initial focus on cancer and genetic diseases, while collaborating with leading pharmaceutical companies to apply our technology platform across a broad range of therapeutic areas. Based on our unique know-how in RNA activation we are expanding the possibilities of RNA-based medicine for patients. For more information, visit www.minatx.com.